Dopharma’s Dexa-ject for pigs receives EU marketing authorisation
Dopharma, a family-owned Dutch manufacturer of veterinary pharmaceuticals, has obtained three new marketing authorisations in the EU, among them Dexa-ject, an inflammation treatment for pigs.
Dexa-ject 2 mg/ml is a dexamethasone injection for use in pigs, cattle, horses, dogs and cats. It is indicated for treatment of inflammatory or allergic conditions. Dexa-ject 2 mg/ml will be available in 15 EU countries (BE, DK, DE, EE, ES,FR, GB, HU, IE, IT, LT, LV, PL, RO, SE).
Related website:
Dopharma
Join 18,000+ subscribers
Subscribe to our newsletter to stay updated about all the need-to-know content in the pigsector, three times a week.
